NL-OMON39935已完成不适用
A clinical evaluation to compare the safety, efficacy and performance of ABSORB everolimus eluting bioresorbable vascular scaffold against XIENCE PRIME everolimus eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions - BVS absorb II
Abbott Vascular International BVBA0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subject must be at least 18 years of age and less than 85 years of age.
- •Subject must agree not to participate in any other clinical investigation for a period of three years following the index procedure. This includes clinical trials of medications and invasive procedures. Questionnairebased studies, or other studies that are non-invasive and do not require medication are allowed.
- •Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the ABSORB scaffold and he/she or his/her legally authorized representative provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee
- •Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia).
- •Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery
- •Subject must agree to undergo all clinical investigation plan-required follow-up visits, exercise testing, blood draw as well as adherence to ESC Guidelines and completion of quality of life questionnaires and of a subject diary to collect information including but not limited to tobacco usage, food intake, daily exercise and body weight.;Angiographic Inclusion Criteria
- •One or two de novo native lesions each located in a different epicardial vessel.
- •If two treatable lesions meet the eligibility criteria, they must be in separate major epicardial vessels (LAD with septal and diagonal branches, LCX with obtuse marginal and/or ramus intermedius branches and RCA and any of its branches).
- •Target lesion(s) must have a visually estimated diameter stenosis of >=50% and <100% with a TIMI flow of >= 1.
- •Lesion(s) must be located in a native coronary artery with Dmax by online QCA of >= 2.25 mm and <= 3.3 mm.
- •Lesion(s) must be located in a native coronary artery with lesion(s) length by on-line QCA of <= 48 mm.
- •Percutaneous interventions for lesions in a non-target vessel are allowed if done >=30 days prior to or if planned to be done 2 years after the index procedure.
- •Percutaneous intervention for lesions in the target vessel are allowed if done >6 months prior to or if planned to be done 2 years after the index procedure.
排除标准
- •General Exclusion Criteria
- •Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin,
- •antiplatelet medications specified for use in the study (clopidogrel and prasugrel and
- •ticlopidine, inclusive), everolimus, poly (L-lactide), poly (DL-lactide), cobalt, chromium,
- •nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be
- •adequately pre-medicated.
- •Subject has a known diagnosis of acute myocardial infarction (AMI) at any time
- •preceding the index procedure and relevant cardiac enzymes (according to local standard
- •hospital practice) have not returned within normal limits at the time of procedure.
- •Evidence of ongoing acute myocardial infarction in ECG prior to procedure
- •Subject has current unstable arrhythmias.
- •Left ventricular ejection fraction (LVEF) < 30%.
- •Subject has received a heart transplant or any other organ transplant or is on a waiting list
- •for any organ transplant.
- •Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days
- •prior to or after the procedure.
- •Subject is receiving immunosuppressant therapy and/or has known immunosuppressive
- •or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus
- •erythematosus, rheumatoid arthritis, severe asthma requiring immunosuppressive
- •medication, etc.).
- •Subject is receiving chronic anticoagulation therapy that can not be stopped and restarted
- •according to local hospital standard procedures.
- •Elective surgery is planned within 2 years after the procedure that will require
- •discontinuing either aspirin, clopidogrel, prasugrel or ticlopidine.
- •Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of
- •<3,000 cells/mm3, or documented or suspected liver disease (including laboratory
- •evidence of hepatitis)
- •Known renal insufficiency (e.g., eGFR <60 ml/kg/m2 or serum creatinine level of >2.5
- •mg/dL, or subject on dialysis).
- •History of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- •Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological
- •attack (TIA) within the past 6 months.
- •Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 years
- •following index procedure. (Female subjects of child-bearing potential must have a
- •negative pregnancy test done within 28 days prior to the index procedure and
- •contraception must be used during participation in this trial)
- •Other medical illness (e.g., cancer or congestive heart failure) or known history of
- •substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause
- •non-compliance with the protocol or confound the data interpretation or is associated
- •with a limited life expectancy.
- •Subject is already participating in another clinical investigation that has not yet reached
- •its primary endpoint.
- •Subject is belonging to a vulnerable population (per investigator*s judgment, e.g.,
- •subordinate hospital staff or sponsor staff) or subject unable to read or write.;Angiographic Exclusion Criteria
- •Target lesion which prevents adequate (residual stenosis at target lesion(s) is <= 40% by
- •visual assessment) coronary pre-dilatation.
- •Target lesion in left main trunk.
- •Aorto-ostial target lesion (within 3 mm of the aorta junction).
- •Target les
研究者
相似试验
已完成
Unknown
Open-label, multicenter clinical study to evaluate the safety and efficacy of ULKOX® OLE vs SoC (e.g., cicatridinum ointment, ointment for anal fissures) in adult patients diagnosed with anal fissuresISRCTN40732544oventure S.L.42
招募中
2 期
evaluation the effect of botulinum toxin type A for treating frown linesskin rejuvenation.IRCT20150101020514N8Imen vaccine alborz Company140
已完成
不适用
Comparative evaluation of the safety and efficacy of long term use of anti-cholinergic, Imidafenacin and Solifenacin, on overactive bladder: a prospective randomized trial.overactive bladderJPRN-UMIN000004354Department of Urology, Kanto Rosai Hospital60
已完成
Unknown
Comparative clinical trial of domestic and foreign fillersKCT0008324Pusan National University Hospital100
进行中（未招募）
不适用
Clinical Evaluation of the AqueSys Implant for the Treatment of ocular hypertension and open angle glaucomaOcular hypertension and open angle glaucomaEye - Diseases / disorders of the eyeACTRN12610000021077Aquesys Inc20